Lipoprotein(a) and cardiovascular disease in diabetic patients

Qibin Qi, Lu Qi

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB100. Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.

Original languageEnglish (US)
Pages (from-to)397-407
Number of pages11
JournalClinical Lipidology
Volume7
Issue number4
DOIs
StatePublished - Aug 2012
Externally publishedYes

Keywords

  • Mendelian randomization
  • cardiovascular disease
  • diabetes
  • lipoprotein(a)
  • prospective studies

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Lipoprotein(a) and cardiovascular disease in diabetic patients'. Together they form a unique fingerprint.

Cite this